Literature DB >> 8037908

A fifty-year follow-up of ocular defects in congenital rubella: late ocular manifestations.

J J Arnold1, E D McIntosh, F J Martin, M A Menser.   

Abstract

Fifty patients born with congenital rubella in 1939-1945 were reviewed in 1967. In 1991 this cohort was again studied and their ophthalmic features are presented here. The presence of two new cataracts and one case of possible choroidal neovascularisation are again noted; apart from these three eyes, the group showed no evidence of other delayed manifestations of the congenital rubella syndrome. A review is given of the ocular complications of the congenital rubella syndrome, with particular emphasis on the late complications.

Entities:  

Mesh:

Year:  1994        PMID: 8037908     DOI: 10.1111/j.1442-9071.1994.tb01687.x

Source DB:  PubMed          Journal:  Aust N Z J Ophthalmol        ISSN: 0814-9763


  4 in total

1.  Lacrimal drainage anomalies in congenital rubella syndrome.

Authors:  Shweta Gupta; Mohammad Javed Ali; Milind N Naik
Journal:  Clin Ophthalmol       Date:  2017-11-09

2.  Identification of new pathogens in the intraocular fluid of patients with uveitis.

Authors:  Jolanda D F de Groot-Mijnes; Lenneke de Visser; Stephanie Zuurveen; Roaldy A Martinus; René Völker; Ninette H ten Dam-van Loon; Joke H de Boer; Gina Postma; Raoul J de Groot; Anton M van Loon; Aniki Rothova
Journal:  Am J Ophthalmol       Date:  2010-08-05       Impact factor: 5.258

Review 3.  Prevalence of adenoviruses as ocular disease causatives in Saudi Arabia.

Authors:  Saleha Kheder Alatawi; Hanan E Alyahyawi; Naseem Akhter; Raed A Alharbi; Waled Am Ahmed; Shaia Saleh R Almalki
Journal:  Saudi J Biol Sci       Date:  2021-12-29       Impact factor: 4.052

4.  Retinal Manifestations of Mitochondrial Oxidative Phosphorylation Disorders.

Authors:  Jin Kyun Oh; Jose Ronaldo Lima de Carvalho; Yan Nuzbrokh; Joseph Ryu; Teja Chemudupati; Vinit B Mahajan; Janet R Sparrow; Stephen H Tsang
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-10-01       Impact factor: 4.799

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.